

January 16, 2007

CURRICULUM VITAE

CLAY M. ANDERSON, M.D.

Associate Professor of Clinical Medicine
Director, Missouri Palliative Care Program
Department of Internal Medicine
Charles and Veta G. Claiborn Faculty Scholar in Cancer Research
Division of Hematology and Medical Oncology
Ellis Fischel Cancer Center/University of Missouri
115 Business Loop 70 West, DC116.71
Columbia, MO 65203
(573) 884-7103
FAX: (573) 884-6051

I. PERSONAL INFORMATION

Birthplace	St. Charles, MO
Birthdate	September 17, 1964
Citizenship	USA
Marital Status	Married, 3 children

II. EDUCATION

<u>Year</u>	<u>Institution</u>	<u>Degree</u>
1982-1986	University of Missouri Columbia, MO	BS (Biochemistry)
1986-1991	Stanford University School of Medicine, Stanford, CA	MD

III. EMPLOYMENT

<u>Years</u>	<u>Title</u>	<u>Employer</u>
1991-1994	Resident, Internal Medicine	University of Colorado Health Sciences Center Denver, CO

1994-1997	Fellowship, Medical Oncology	University of Texas M.D. Anderson Cancer Center Houston, TX
1997-2003	Assistant Professor Division of Hematology and Medical Oncology	Ellis Fischel Cancer Center Columbia, MO
2003-present	Associate Professor Division of Hematology And Medical Oncology	Ellis Fischel Cancer Center Columbia, MO

IV. AWARDS

1985	Phi Lambda Upsilon Biochemistry Student of the Year
1985	Greek Active Scholar of the Year
1989	Medical Student Alumni Scholar
1990	Lowell Glasgow Student Research Award, Western Society for Pediatric Research Stanford University School of Medicine
1991	Dean's Awards in Research, Teaching, and Community Service
1994	Gold Apple Teaching Award, University of Colorado Health Sciences Center
1995	Clifton D. Howe Outstanding Clinical Fellow of the Year, Univ. of Texas-M.D. Anderson Cancer Center
1999	Excellence in Patient Education, Physician Category, University of Missouri Health Sciences Center
2002	Service Quality Hero Weekly Recognition University of Missouri Health Care
2003	Order of Socrates for Excellence in Teaching University of Missouri-Columbia School of Medicine
2004	Charles and Veta G. Claiborn Faculty Scholar in Cancer Research, Faculty Endowment

- 2005 Service Quality Hero Monthly Recognition
University of Missouri Health Care
- 2006 Alpha Omega Alpha, Honorary Faculty Member
University of Missouri

V. **ACTIVITIES AND ORGANIZATIONS/MEMBERSHIPS**

- Member,
American Medical Association
- Member,
American College of Physicians/ Am. Soc. Internal Medicine
- Member,
American Society of Clinical Oncology
- Member,
American Association for Cancer Research
- Member,
Boone County Medical Society
Board of Directors 2000-present
CME Committee chair 2001-present
- Member,
Missouri State Medical Association
- Member,
Cancer and Leukemia Group B
- Member,
Missouri Cancer Consortium
- Member,
Sigma Xi Scientific Research Society
- Member
Past Chair, 2000-2002
Board Member 1998-2006
Missouri End of Life Coalition

VI. **LICENSURE**

- 1993 Colorado (lapsed)

1995 Texas (inactive)

1997 Missouri

VII. EDITORIAL FUNCTIONS

1998-2000 Associate Editor for the American Society of Clinical Oncology
Programs & Proceedings

2003-present Editorial Board
Hematology/Oncology News International

VIII. BOARD CERTIFICATION

1994 American Board of Internal Medicine
Internal Medicine

1997 American Board of Internal Medicine
Medical Oncology

2006 American Board of Internal Medicine
Recertification, Internal Medicine

2006 American Board of Hospice and Palliative Medicine
Diplomate, Hospice and Palliative Care

IX. ADMINISTRATIVE RESPONSIBILITIES AND LEADERSHIP

1987-1990 Committee on the Well-Being of Medical Students
Stanford University School of Medicine

2000-2001 Admissions Committee- Stanford School of Medicine,
Interviewing and File Review

2000-2001 Chair, Laboratory Process Task Force
Ellis Fischel Cancer Center

1997-2006 Education Subcommittee
Ellis Fischel Cancer Center
Chairman, 1998-2005

1998-Present Pain and Palliative Care Committee
Ellis Fischel Cancer Center
Co-Chairman, 1998-2000

1998-2001	Executive Committee Clinical Affairs Council, Department of Internal Medicine University of Missouri School of Medicine
1998-2007	Board Member Missouri End of Life Coalition Chairman, 2000-2002
1998-2006	Ellis Fischel Cancer Center Annual Oncology Conference Planning Committee Chair, 1999-2002
1999-Present	Member, Clinical Cancer Committee Ellis Fischel Cancer Center
2000-2001	Clinic Director Ellis Fischel Cancer Center
2000-2003	Physician Service Quality Leadership Taskforce University Hospital and Clinics
2000-present	Palliative Care Task Force/Committee University of Missouri Hospital and Clinics
2001-2003	Member, Dean's Advisory Council
2001-2005	Medical Director, 5 East/Ellis Fischel Inpatient Unit and Symptom Evaluation Unit
2002-2005	Chemotherapy CQI Committee EFCC/University Hospital
2002-2005	Faculty Advisory Council, Univ. of Missouri – Columbia School of Medicine
2002-present	Melanoma Hope Network Member, Board of Directors Founding and Current Medical Director
2003-2005	Director of Clinical Services Ellis Fischel Cancer Center
2003-present	Director of Pain and Palliative Care Ellis Fischel Cancer Center
2004-2006	Faculty Retention and Support Committee/Faculty Orientation and Retention Committee, Univ. of Missouri – Columbia School of Medicine

2004-2006	Promotion and Tenure Committee Department of Internal Medicine University of Missouri – Columbia School of Medicine
2005-present	Clinical Ethics Committee and Clinical Ethics Consultation Service University of Missouri – Columbia School of Medicine
2005-2006	Communications Committee Service Excellence Initiative, University of Missouri Health Care
2006-present	Patient Centered Care Interest Group, Univ. of Missouri – Columbia School of Medicine
2006-present	Director, Missouri Palliative Care Program, University of Missouri Health Care

X. RESEARCH EXPERIENCE

Undergraduate	Research Associate - Spring 1986; University of Missouri-Columbia. Department of Biochemistry. Cell cycling and oncogenesis.
Medical School	Research Assistant - June-September 1987; Washington University School of Medicine, Division of Respiratory and Critical Care Medicine. Fibronectin/fibronectin receptor characterization. Research Assistant - March 1988-June 1989; Stanford University School of Medicine, Neonatal Vascular Biology Laboratory, Division of Neonatology. Endothelial cell/smooth muscle cell interactions.
Residency	Clinical Research Center Project - November-December 1992; Division of Hematology/Oncology. Natural killer cell activity in metastatic melanoma patients on melatonin therapy.

Fellowship	July 1995; Department of Tumor Biology. The role of monocyte/macrophage tumoricidal activity in the efficacy of biochemotherapy in patients with advanced malignant melanoma.
1998-Present	Clinical Consultant, MSH-like peptide radionuclide conjugate for melanoma therapy, T. Quinn, PI
2002-present	Clinical Consultant and Co-Investigator to Principal Investigator Jane Armer, PhD on Breast Cancer and Melanoma Lymphedema Evaluation Research Program University of Missouri-Columbia, Sinclair School of Nursing
2002-2005	Advisor to Benjamin Liess, MS4 Cutaneous Melanosis is Metastatic Melanoma IRB Approved Project
2002-2003	Advisor to Joy Wenger, MS4 Spirituality and Distress in Dying Cancer Patients IRB Approved Project
2004-present	MU2020 Patient Centered Care Grant The Impact of Storytelling on the Experience of M3 Students on an Outpatient Oncology Rotation IRB Approved Project
2004-2006	Co-Investigator with Yinfa Ma, PhD, Department of Chemistry, UMR, Prognostic Value of Urinary Pteridines in Lung Cancer IRB Approved Project

XI. TEACHING

Undergraduate	August-December 1984; Undergraduate Teaching Assistant for Honors General, Paul Agris, Ph.D., professor. Department of Biology-University of Missouri-Columbia
Medical School	Autumn 1987-1988; Teaching Assistant in Human Anatomy, Larry Mathers, M.D., Ph.D., course director, 100% appointment. Stanford University School of Medicine

Winter 1987-1988; Teaching Assistant in Neurobiology, Stanford University School of Medicine, 50% appointment, U. J. McMahon, Ph.D., course director.

Autumn 1988-1989; Teaching Assistant in Human Anatomy at Stanford University School of Medicine, 50% appointment.

Faculty

IPC Block 1 – “Patient-Physician Communication” and “Medical Interviewing” 2005

IPC Block 2 - “Introduction to Physical Diagnosis”, MU School of Medicine, 1997, 1998, 1999

IPC Block 3 – Block Co-Tutor (Psychosocial Aspects of Medicine) 2004 – 2006

PBL Block 3 – End of Life/Palliative Care Lecture 2002 – present

PBL Block 5 – Two Lectures on principles of cancer treatment -- 2001-present

PBL Block 6 – Two lectures on chemotherapy – 2003-present

PBL Block 7 – Two lectures: pain management and heme/onc procedures – 2003 – present

Management Lecture Series (Medicine Clerkship M3s - Once every two blocks)

1. Thromboembolic Disorders, 1997-1998
2. Chemotherapy Management, 1998-2003
3. End of Life Care, 1999-2003

Advanced Physical Diagnosis with M2s-1998-2004

Internal Medicine Grand Rounds:

Medical Mysteries

“Vitiligo and melanoma: What’s the Connection”
1999

Ethics of Phase I Trials -- 2003

The Power of Stories: Medicine, Mystery, and Miracles --
May 2004

Chronic Pain in Sickle Cell Anemia -- October 2004

Palliative Care Principles – September 2005

Palliative Care Program Development – October 2006

Cardiology Grand Rounds 2001

“End of Life Care: Expanding Principles & Practices
Outside of Oncology”

ENT Grand Rounds 2001

“Systemic Therapy of Advanced Melanoma”

Neurology and Neurosurgery Grand Rounds 2003 – Update
on Management of Brain Tumors and 2005 Palliative Care

Psychiatry Grand Rounds – The Power of Stories, 2003,
and Palliative Care, 2005

Orthopedics Teaching Conference 2003

“Systemic therapy for bone and soft tissue sarcomas”

Healer’s Art Certificate Class

Group Mentor

UMC School of Medicine

2004

Oncology Grand Rounds 2005 -- Palliative Care

Ethics Grand Rounds June 2006

Palliative Sedation in the Dying: Ethics and Realities

VAMC Physician/Staff Conference December 2006

Harry S. Truman VA Medical Center

Pain and Symptom Management in End of Life Care: Are
we there? Who decides? Does it matter?

Monthly Physician/Staff Grand Rounds January 2007

Missouri Rehabilitation Center – Mount Vernon, MO

Palliative and End of Life Care; Whole People, Precious
Days

XI. INVITED PRESENTATIONS

Over 150 invited presentations since 1996 from Long Island, NY to Galveston, TX to Denver, CO on systemic therapy for advanced melanoma, treatment strategies for metastatic renal cell carcinoma, concepts of immunotherapy, pain management, and palliative care/end of life care.

XII. GRANT SUPPORT

<i>Study</i>	<i>Funding Source</i>	<i>Direct Costs</i>	<i>Total Contract Period</i>
Fellowship Award	American Cancer Society Texas Division of Oncology Research	\$ 3,600	1996-1997
Melanoma Research	MDACC Skin Center Friedman Fellowship	\$ 30,000	1996-1997
Phase II Head and Neck Trial	Bristol Myers Squibb	\$ 40,650	12-14-96 to 12-13-99
Melanoma Research	Harold F. Bean	\$ 15,000	1997
Melanoma Research	Maxim Pharmaceutical	\$ 13,732	12-22-97 to 03-31-02
Phase III Melanoma IL-2/Maxamine	Maxim	\$ 79,268	12-01-97 to 11-30-98
Unrestricted Education Grant	Chiron Therapeutics	\$ 6,500	1998
Univ. of Colo. Ph II Pre-op Biochemo	Schering	\$ 9,393	04-02-98 to 04-01-99
Phase III Stage 4 Bladder	Lilly	\$ 25,152	12-01-97 to 11-30-99
Phase II Modified Biochemotherapy	Schering	\$ 9,756	09-18-98 to 08-31-99
Phase III CVAX Stage 4 Melanoma	NCI/JWCI	\$ 14,634	09-18-98 to 09-14-01
Phase III CVAX Stage 3 Melanoma	NCI/JWCI	\$ 34,756	09-15-98 to 09-14-02
Multicent. Ph II Pre-op Biochemo.	Schering	\$ 8,130	06-21-99 to 06-20-00
Multicent. Ph II Pre-op Biochemo.	Chiron	\$ 20,325	06-24-99 to 06-23-00
Multicent. Ph II Outpt. Chemoimmuno.	Chiron	\$ 16,260	10-01-99 to 09-30-00
Multicent. Ph II Outpt. Chemoimmuno.	Schering	\$ 8,130	10-01-99 to 09-30-00
ILIAD Multicent. Ph II in Met RCC	Quintiles – Chiron	\$ 15,000	10-18-99 to 10-17-00
Phase II Taxol plus Primvastat	Aguoron	\$110,569	04-18-00 to 04-17-02
Phase II Trial of PEG Roferon	Roche-PEG	\$ 69,192	01-04-01 to 03-31-02
Melanoma Research	Chiron Corp.	\$ 20,325	03-28-01 to 03-27-02
Phase II BCT/IT Maintenance	JWCI	\$ 30,081	04-17-01 to 04-16-03
Phase III CC5013 Melanoma study	ICON	\$ 86,658	12-31-02 to 12-30-04
Phase III HSPPC-96 Vac. vs. chemo Melanoma study	Antigenics Inc.	\$ 76,574	06-20-03 to 06-19-05
Phase II Taxol/STA4837 Melanoma Study	Synta, Inc	\$ 30,799	06-04 to present
Phase I Karenitecin Study	Bionumerik, Inc.	\$ 15,000	04-04 to present
Phase III Breast Tavocept Study	Bionumerik, Inc.	\$ 81,000	04-04 to 10-06

Biovex OncoVex Melanoma Study	Biovex, Inc.	\$118,662	01-06 to 10-06
Phase III Mederex Melanoma Study	Mederex, Inc.	\$ 52,313	10-04 to present
Phase III Lilly Enzostaurin GBM Study	Lilly Oncology, Inc.	\$ 50,953	6-06 to 05-07
Phase I/II Amplimexon Study	Amplimed, Inc.	\$132,599	12-05 to 12-07
Biochemo/PCI Study	Chiron/Novartis	\$ 22,000	6-05 to present
Phase III BMS 022 Melanoma Study	Bristol Meyer Squibb, Inc	\$ 66,500	6-06 to present
BMS 025 Maintenance Melanoma Study	Bristol Meyer Squibb, Inc	\$ 54,215	11-06 to present

XIII. PUBLICATIONS

Manuscripts

1. Benitz W, Kelley R, **Anderson C**, Lorant D, Bernfield M. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. *Am J Respir Cell Mol Biol*, 2:13-24, 1990.
2. **Anderson, CM**. Sodium chloride treatment of amphotericin B nephrotoxicity--standard of care? *Western J Med*. 162: 313-317, 1995.
3. **Anderson CM**, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. *Oncology*. 9 (11): 1149-1158, 1995.
4. **Anderson CM**, Walters RS, Hortobagyi GN. Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early stage breast cancer. *Am J Clin Oncol (CCT)* 19: 556-568, 1996.
5. **Anderson CM**, Buzaid AC, Sussman JJ, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Sewa S, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. *Melanoma Res*. 8(2):149-155,1998
6. **Anderson CM**, Pusztai L, Palmer, J, Cabanillas F, Ellerhorst J. Coincident renal cell carcinoma and non-Hodgkin lymphoma: The MD Anderson experience and review of the literature. *J Urol* 159(3):714-717, 1998.
7. **Anderson CM**, Bueso-Ramos CE, Wallner SA, Albitar M, Rosenzweig TE, Koller CA. De novo acute Myelogenous Leukemia associated with plasma cell dyscrasia: two cases and an update of literature. *Leukemia & Lymphoma*.32 (3-4): 385-390, 1999.
8. **Anderson CM**, Buzaid AC. The Changing Prognosis of Melanoma. *Current Oncology Reports* 2:322-328. 2000.
9. Wooldridge JE; **Anderson CM**; Perry MC: Corticosteroids in advanced cancer, *Oncology* 15(2), 225-234, February 2001.

10. **Anderson, CM.** Principles of end-of-life care. *Oncology Review*. Ellis Fischel Cancer Center. University of Missouri Health Sciences Center. pp. 1-3. Fall 2001.
11. **Anderson, CM.** Medical treatment for advanced melanoma. *Oncology Review*. Ellis Fischel Cancer Center. University of Missouri Health Sciences Center. pp. 1-2. Winter. 1999.
12. **Anderson, CM.** Patient care evaluation study: cutaneous melanoma. 2001 Cancer Program Annual Report. Ellis Fischel Cancer Center. University of Missouri Health Care. pp. 17-19, 2001.
13. Gibbs P, **Anderson C**, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. *Cancer* 94: 470-476, 2002.
14. Fu MR, **Anderson CM**, McDaniel R, Armer J. Patients' perceptions of fatigue in response to biochemotherapy for melanoma: a preliminary study. *Oncology Nursing Forum*. 29(6): 961-966, 2002.
15. **Anderson, CM.** Pain relief at the end-of-life: a clinical guide. *Missouri Medicine*. 99(10): 556-559. November/December 2002.
16. Cravens D, **Anderson CM.** Relieving non-pain suffering at the end-of-life. *Missouri Medicine*. 100(1): 76-81. January /February 2003.
17. Christianson DF, **Anderson CM.** Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma. *Seminars in Oncology*. 30(3): 369-374. 2003.
18. **Anderson CM.** Melanoma Vaccines 2004. *Oncology Review*. Ellis Fischel Cancer Center. University of Missouri Health Sciences Center. pp. 1-3. Spring 2004.
19. Weiner R, **Anderson C**, Edison K, Greer E. Melanoma reporting in Missouri. *Missouri Medicine*. 101(6): 598-601. 2004.
20. Malhotra V, Dorr VJ, Lyss AP, **Anderson CM**, Westgate S, Reynolds M, Barrett B, Perry MC. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. *Clinical Breast Cancer*, 5(5):377-84. 2004.
21. Lewis K, Gibbs P, O'Day S, Richards J, Weber J, **Anderson CM**, et. al. A phase II study of biochemotherapy for advanced Melanoma incorporating temozolomide decrescendo interleukin-2 and GM-CSF. *Cancer Investigation*. 23: 303-308. 2005.
22. Porock D, Beshears B, Hinton P, **Anderson CM.** Nutritional, functional, and emotional characteristics related to fatigue in patients during and after biochemotherapy. *Oncology Nursing Forum*. 32(3): 661-667. 2005.

23. Lewis KD, Robinson WA, McCarter M, Pearlman N, O'Day SJ, **Anderson C**, Amatruda TT, Baron A, Seng C, Becker M, Dollarhide S, Matijevich K, Gonzalez R. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. *J Clin Oncol.* 24(19):3157-3163, 2006.

Books

1. Companion Handbook to the Chemotherapy Sourcebook. Perry MC, **Anderson CM**, Dorr V, Wilkes, JD, editors. Williams & Wilkins Publishing, Baltimore, MD. 1999.
2. Companion Handbook to the Chemotherapy Sourcebook. 2nd Edition. Perry MC, **Anderson CM**, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.

Book Chapters

1. **Anderson CM**, Legha SS, Tabacof J. "Malignant melanoma: biology, diagnosis, and management." in *Medical Oncology: A Comprehensive Review*. 2nd Ed. Pazdur R, ed. PRR, Inc., Huntington, NY. pp. 493-509, 1995.
2. **Anderson CM**, Buzaid AC, Grimm EA. "The interaction of chemotherapy and biological response modifiers in the treatment of melanoma." in *Drug Resistance*. Hait WN, ed. Kluwer Academic Publishers, Inc., Norwell, MA. pp. 357-380, 1996.
3. **Anderson CM**, Buzaid AC, Ali-Osman F, Braunschweiger PG, Grimm EA. "Biochemotherapy in the treatment of advanced melanoma: Clinical results and potential mechanisms of anticancer activity." in *Progress in Anti-Cancer Chemotherapy*. Khayat D, Hortobagyi GN., eds. Blackwell Science, Inc., Cambridge, MA. pp. 68-87, 1997.
4. **Anderson CM**. "Poor translation, good prognosis." In *Medical Mysteries: Case based learning in internal medicine*. Weber KT, ed. University of Missouri Printing Services, Columbia, MO, 1997.
5. **Anderson CM**, Rasool H. "Biologic Therapy of Cancer." In *Hematology/Oncology Secrets*. 2nd Ed. Woods ME, Philips GK, eds., Hanley & Belfus, Philadelphia, PA pp. 206-210, 1998.
6. **Anderson CM**, Wilkes JD. "Malignant melanoma." in *Companion Handbook to the Chemotherapy Sourcebook*. Perry MC, Anderson CM, Dorr V, Wilkes, JD, editors. Williams & Wilkins Publishing, Baltimore, MD. pp. 57-64, 1999.
7. **Anderson CM**. "Chemotherapeutic agents-drug profiles." in *Companion Handbook to the Chemotherapy Sourcebook*. Perry MC, Anderson CM, Dorr V, Wilkes, J, editors. Williams & Wilkins Publishing, Baltimore, MD. pp. 407-473, 1999.

8. **Anderson, CM**, Perry, MC, Donehower RC. “Chemotherapy” in Clinical Oncology, 2nd ed., Armitage et al, eds., Churchill Livingstone, Philadelphia, PA, 2000.
9. **Anderson CM**. “Chemotherapy of Melanoma” in The Chemotherapy Sourcebook, 3rd ed. Perry MC, ed. Lippincott, Williams, and Wilkins, Philadelphia, PA, 2001.
10. **Anderson CM**, Haider S. “Biologic Therapy of Cancer.” In Hematology/Oncology Secrets. 3rd Ed. Woods ME, Philips GK, eds., Hanley & Belfus, Philadelphia, PA pp. 206-210, 2003.
11. Haider SN, **Anderson CM**. “Malignant melanoma.” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
12. Schultheis CP, **Anderson CM**. “Adult Central Nervous System Tumors” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
13. Al-Khater AM, **Anderson CM**. “Head and Neck Cancer” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
14. Haider SN, **Anderson CM**. “Renal Cell Carcinoma” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
15. Haider SN, **Anderson CM**. “Adult Soft Tissue Sarcomas” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
16. Schultheis CP, **Anderson CM**. “Neuroblastoma” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
17. Schultheis CP, **Anderson CM**. “Osteosarcoma” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
18. Schultheis CP, **Anderson CM**. “Retinoblastoma” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC,

- Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
19. **Anderson CM**. “Drug Profiles” in Companion Handbook to the Chemotherapy Sourcebook 2nd Edition. Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE, editors. Lippincott, Williams, & Wilkins, Baltimore, MD. 2004.
 20. **Anderson, CM**, Perry, MC, Donehower RC. “Chemotherapy” in Clinical Oncology, 3rd ed., Armitage et al, eds. Churchill Livingstone, Philadelphia, PA, 2004.
 21. **Anderson CM**. “Systemic Therapy for Cancer” in Cancer Principles and Practice of Oncology Review. Govindan R, editor. Lippincott, Williams, and Wilkins, Philadelphia, PA, 2005.

Abstracts

1. **Anderson C**, Kelley R, Lorant D, Benitz W. Purification of an endothelial heparan sulfate proteoglycan inhibitor of smooth muscle cell proliferation. Clinical Research. Vol. 38 (1): 169A, 1990.
2. P. Gibbs, S. O’Day, J. Richards, J. Weber, **C. Anderson**, R. Gonzalez. A Multicenter Phase II Study of Modified Biochemotherapy (BCT) for Stage IV Melanoma Incorporating Temozolomide, Decrescendo Interleukin-2 (IL-2) and GM-CSF. Proceedings of American Society of Clinical Oncology. 2000.
3. **Anderson CM**, Cunningham M, Peck R, Perry M, Evans W. Clinical Pathway for Hospitalized Terminally Ill. No. 3012 Proceedings of American Society of Clinical Oncology 2001.
4. Malhotra V, Dorr VJ, Lyss AP, Wooldridge JE, **Anderson CM**, Reynolds M, Perry MC. Neoadjuvant and Adjuvant Chemotherapy (CT) with Doxorubicin and Docetaxel (DD) with Surgery and Radiation in Locally Advanced Breast Cancer. No. 1771 Proceedings of American Society of Clinical Oncology, 2001.
5. O’Day S, Aikins M, Weber J, Thompson J, **Anderson CM**, Bon Zalez R, Lutzky J, Amatruda J, Hersh E, Boasber P. A phase II multi-center trail of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metatastic melanoma (MM). Abstract No. 7503. 2005 ASCO annual meeting.
6. **Anderson CM**, Floyd J, Cunningham M, Reeder T, Hoffman K, Boren S. A randomized study of a patient narrative (storytelling) medical education process for third year medical students compared to standard clinical experience in an academic oncology practice. Abstract No. 8265. 2005 ASCO annual meeting.

7. Kim KB, Legha SS, Gonzalez R, **Anderson C**, Papadopoulos NE, Eton O, Plager C, Roe A, Liu P, Bedikian AY. A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon- α -2b (IFN) in patients (pts) with high risk for melanoma recurrence. Abstract No. 8003. 2006 ASCO annual meeting.

Poster/Abstracts

1. **Anderson C**, Berl T. An unusual case of parathyroid adenocarcinoma presenting as oliguric renal failure and bilateral femoral head fractures. Presented at the 1993 Denver-Area Annual ACP Meeting, Denver, Colorado, May 27, 1993.
2. **Anderson C**, Buzaid A, Ali-Osman F, Braunschweiger P, Grimm E. Nitric oxide levels and response in stage III melanoma patients receiving concurrent biochemotherapy. Proc Am Assoc Cancer Res 37: 464, 1996.
3. **Anderson C**, Buzaid A, Sussman J, Lee J, Ali-Osman F, Braunschweiger P, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha S, Grimm E. Elevated nitric oxide (NO) and neopterin levels and response in stage III melanoma patients receiving concurrent biochemotherapy. Proc Am Assoc Cancer Res 38: 403, 1997.
4. **Anderson C**, Buzaid A, Sussman J, Lee J, Leghn S, Grimm E. "Nitric oxide (NO) neopterin and cytokine levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. 4th WHO World Conference on Melanoma, Sydney, Australia, June 10-14, 1997.